Goldman Sachs Group Inc Pacira Bio Sciences, Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,309,988 shares of PCRX stock, worth $31.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,309,988
Previous 1,308,901
0.08%
Holding current value
$31.2 Million
Previous $31.3 Million
7.92%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding PCRX
# of Institutions
261Shares Held
48.9MCall Options Held
118KPut Options Held
63.7K-
Black Rock Inc. New York, NY8.01MShares$190 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.2MShares$124 Million0.0% of portfolio
-
Doma Perpetual Capital Management LLC Miami, FL2.7MShares$64.2 Million23.38% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$51.4 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.14MShares$50.8 Million0.08% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.09B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...